Understanding heart disease in young people with type 2 diabetes
Official title: Youth-onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study
Run by National Institutes of Health Clinical Center (CC) · NCT06730113 · Data updated 2026-11-12
This study looks at what causes heart disease in young people aged 12 to 25 with type 2 diabetes, those who are overweight, and healthy peers to see how their heart health compares over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 12 Years to 25 Years |
| Sex | All |
| Enrollment | 930 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 2 sites (Washington D.C., District of Columbia and 1 other locations) |
| Status | Recruiting |
| Started | March 12, 2025 |
| Main results expected | October 31, 2033 |
| Study ends | October 31, 2033 |
| Registry record updated | September 17, 2026 |
| Trial ID | NCT06730113 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 12 to 25 years with type 2 diabetes, those who are overweight, or healthy lean peers.
✕Probably not a fit
Patients outside the age range of 12 to 25 years or those without type 2 diabetes, overweight, or lean status may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the factors contributing to cardiovascular disease in youth aged 12 to 25 years with type 2 diabetes, those who are overweight, and healthy lean peers. Participants will visit the NIH clinic annually for up to 25 years, undergoing various tests including blood, urine, and stool sample collection, as well as cardiovascular assessments. The study will compare pulse wave velocity and augmentation index among the different groups to understand the pathophysiological features of cardiovascular disease in youth-onset type 2 diabetes.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of cardiovascular risks in young individuals with type 2 diabetes.
How similar studies have gone: While there have been studies on cardiovascular disease in adults with diabetes, this specific focus on youth-onset type 2 diabetes is relatively novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: To be eligible to participate in this study, an individual must meet the following criteria according to their group: Four categories of participants will be included in this study and the inclusion criteria for each group are given below: 1. Participants with Y-T2DM 1a.Age 12-25 years 1b.Type 2 diabetes mellitus as defined by fasting blood glucose \>= 126 mg/dL OR postprandial blood sugar \>= 200 mg/dL OR Hemoglobin A1c \>= 6.5% per American Diabetes Association Criteria and one element from the medical history consistent with ADA or AAP guidelines including: family history of diabetes and obesity, maternal or personal history of gestational diabetes, high-risk race and ethnicity, history of cardiovascular disease, hypertension, dyslipidemia, polycystic ovary syndrome, physical inactivity, other clinical conditions associated with insulin resistance (e.g. severe obesity, acanthosis nigricans, prediabetes), small or large for gestational age birth weight, history of breastfeeding, gestational history of illicit drugs including alcohol, smoking OR documentation of type 2 diabetes diagnosed at \<=25 years of age with verified medical history (as above). 2\. Youth with overweight/ obesity (Y-OW) 2a. Age 12-25 years 2b. For participants \< 18 years of age, BMI \>= 85th percentile (overweight) and \>= 95th percentile (obesity) for age and sex OR 2c. For participants \>= 18 years of age, BMI \>=25\<30 kg/m\^2 (overweight) or \>=30 kg/m\^2 (obesity) 2d. Participants with obesity may have a diagnosis of prediabetes, defined as fasting blood glucose 100-125 mg/dL OR postprandial blood sugar 140-199 mg/dL OR HbA1c 5.7-6.4 percent (either during testing at NIH or as previously documented on outside medical record). 3\. Healthy control lean participants (Y-Lean) 3a. Age 12-25 years 3b. For participants \< 18 years of age, BMI \<= 85th percentile for age and sex OR 3c. For participants \>=18 years of age, BMI 18-24.99 kg/m\^2. 3d. HbA1c \<5.7 percent (either during testing at NIH or as previously documented on outside medical record). 4\. Biological parents of Y-T2DM, Y-OW and Y-Lean participants 4a. Biological parent of enrolled Y-T2DM, Y-OW and Y-Lean by self-report. EXCLUSION CRITERIA: An individual who meets any of the following criteria for their specific group will be excluded from participation in this study: 1\. Y-T2DM, Y-OW and Y-Lean Participants: 1a. Type 1 diabetes or the presence of \>2 diabetes auto-antibodies (e.g., GAD-65, IA-2 antigen, Zinc transporter 8 autoantibodies). 1. b. Medical, psychiatric or cognitive disorders that will, in the opinion of the investigators, limit the subject s ability to comply with study procedures (specific obesity-related comorbidities are explicitly permitted, including hypertension, hyperlipidemia, obstructive sleep apnea and non-alcoholic steatohepatitis). 1c. Serious medical illnesses or diseases thought to alter metabolism (including moderate to severe renal disease (\< 30 mL/min/1.73m\^2), congenital heart disease, Cushing s syndrome, cancer, or other metabolic diseases associated with diabetes or excess weight). 1d. For participants enrolled at the NIH, dietary allergies, intolerances or eating patterns that would preclude them from consuming metabolic meals. 1e. Unwilling to comply with all study procedures or to adhere to Lifestyle Considerations throughout study duration. 1f. Pregnancy at the time of the screening visit. 1g. Clinically significant anemia OR Hematocrit below the lower limit of normal for age and sex cutoffs. 1. h. For Y-OW Participants- Meet lab and medical history criteria for Y-T2DM as described in inclusion criterion 1b above. 2\. Y-Lean participants: In addition to the above exclusion criteria, any Y-Lean participant who meets any of the following additional criteria will be excluded from the study: 2a. Current use of prescription or non-prescription medication. Certain exceptions are permitted, including topical medications, vitamins, and hormonal contraceptives. Other medications may be permitted at the discretion of the investigators. 2b. Recent (past 2 months) use of drugs or supplements that alter glucose or lipid metabolism (e.g., niacin, fish oil, red yeast rice) 2c. History of diabetes or abnormal glucose tolerance 2d.. Abnormal screening labs, including the following: i) ALT or AST \>2 times the upper limit of normal ii) Glycosuria iii) Low eGFR (\<90 mL/min/1.73m\^2)Any other abnormality that, in the opinion of the investigator, will increase risk to the subject from participation, or interfere with interpretation of study data 2e. Meet lab and medical history criteria for Y-T2DM as described in inclusion criterion 1b above. 3\. Biological Parents -No Exclusion Criteria
Where it's running
-
Children's National Hospital (CNH)
Washington D.C., District of Columbia, United States Recruiting -
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Stephanie T Chung, M.D. — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study coordinator: Lilian S Mabundo
- Email: lilian.mabundo@nih.gov
- Phone: (240) 383-9379
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes
This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.
-
Switching to Zenagamtide from Semaglutide in adults with overweight or obesity, with or without type 2 diabetes
This study tests whether adults who are already taking semaglutide can successfully switch to zenagamtide at different doses to see which dose works best.
-
Using Multimodal Ultrasound to Check Muscle Mass in Metabolic Disease Patients
This study tests whether a multimodal ultrasound approach can accurately measure muscle mass in people with metabolic syndrome, obesity, sarcopenia, or type 2 diabetes.
-
GUB-UCN2 in healthy, obese, and T2D adults: a first-in-human safety and pharmacology study
This study tests GUB-UCN2 to see if it is safe and tolerable and how it behaves in the body in healthy adults, people with obesity, and people with obesity with or without type 2 diabetes.
-
Two doses of CagriSema plus one dose of Semaglutide for weight loss in obesity with or without type 2 diabetes
This study tests whether two doses of CagriSema, plus a dose of Semaglutide, help adults with obesity (with or without type 2 diabetes) lose weight.
-
Semaglutide's effects on heart and muscle mass
This project will use MRI scans and strength tests over 12 months to see if semaglutide changes body and heart muscle in adults starting the medication.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.